These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 10658679)

  • 1. Abl kinase but not PI3-kinase links to the cytoskeletal defects in Bcr-Abl transformed cells.
    Gaston I; Stenberg PE; Bhat A; Druker BJ
    Exp Hematol; 2000 Jan; 28(1):77-86. PubMed ID: 10658679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of the tyrosine kinase inhibitor imatinib mesylate on a Bcr-Abl-positive cell line: suppression of autonomous cell growth but no effect on decreased adhesive property and morphological changes.
    Nishihara T; Miura Y; Tohyama Y; Mizutani C; Hishita T; Ichiyama S; Uchiyama T; Tohyama K
    Int J Hematol; 2003 Oct; 78(3):233-40. PubMed ID: 14604282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BCR-ABL-induced adhesion defects are tyrosine kinase-independent.
    Wertheim JA; Forsythe K; Druker BJ; Hammer D; Boettiger D; Pear WS
    Blood; 2002 Jun; 99(11):4122-30. PubMed ID: 12010816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adhesion to fibronectin selectively protects Bcr-Abl+ cells from DNA damage-induced apoptosis.
    van der Kuip H; Goetz AW; Miething C; Duyster J; Aulitzky WE
    Blood; 2001 Sep; 98(5):1532-41. PubMed ID: 11520804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BCR/ABL induces multiple abnormalities of cytoskeletal function.
    Salgia R; Li JL; Ewaniuk DS; Pear W; Pisick E; Burky SA; Ernst T; Sattler M; Chen LB; Griffin JD
    J Clin Invest; 1997 Jul; 100(1):46-57. PubMed ID: 9202056
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of transcriptional targets associated with the expression of p210 Bcr-Abl.
    Hickey FB; Cotter TG
    Eur J Haematol; 2006 May; 76(5):369-83. PubMed ID: 16494625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HOXA10 expression induced by Abl kinase inhibitors enhanced apoptosis through PI3K pathway in CML cells.
    Sugimoto Y; Nakamura S; Okinaka K; Hirano I; Ono T; Shigeno K; Shinjo K; Ohnishi K
    Leuk Res; 2008 Jun; 32(6):962-71. PubMed ID: 18190961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BCR-ABL binds to IRS-1 and IRS-1 phosphorylation is inhibited by imatinib in K562 cells.
    Traina F; Carvalheira JB; Saad MJ; Costa FF; Saad ST
    FEBS Lett; 2003 Jan; 535(1-3):17-22. PubMed ID: 12560071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphatidylinositol-3 kinase inhibitors enhance the anti-leukemia effect of STI571.
    Klejman A; Rushen L; Morrione A; Slupianek A; Skorski T
    Oncogene; 2002 Aug; 21(38):5868-76. PubMed ID: 12185586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deregulation of the Wilms' tumour gene 1 protein (WT1) by BCR/ABL1 mediates resistance to imatinib in human leukaemia cells.
    Svensson E; Vidovic K; Lassen C; Richter J; Olofsson T; Fioretos T; Gullberg U
    Leukemia; 2007 Dec; 21(12):2485-94. PubMed ID: 17728783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of autophagy by Imatinib sequesters Bcr-Abl in autophagosomes and down-regulates Bcr-Abl protein.
    Elzinga BM; Nyhan MJ; Crowley LC; O'Donovan TR; Cahill MR; McKenna SL
    Am J Hematol; 2013 Jun; 88(6):455-62. PubMed ID: 23440701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Global effects of BCR/ABL and TEL/PDGFRbeta expression on the proteome and phosphoproteome: identification of the Rho pathway as a target of BCR/ABL.
    Unwin RD; Sternberg DW; Lu Y; Pierce A; Gilliland DG; Whetton AD
    J Biol Chem; 2005 Feb; 280(8):6316-26. PubMed ID: 15569670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X.
    Oetzel C; Jonuleit T; Götz A; van der Kuip H; Michels H; Duyster J; Hallek M; Aulitzky WE
    Clin Cancer Res; 2000 May; 6(5):1958-68. PubMed ID: 10815921
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells.
    Yu C; Krystal G; Varticovksi L; McKinstry R; Rahmani M; Dent P; Grant S
    Cancer Res; 2002 Jan; 62(1):188-99. PubMed ID: 11782377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Different target range and cytotoxic specificity of adaphostin and 17-allylamino-17-demethoxygeldanamycin in imatinib-resistant and sensitive cell lines.
    Barnes DJ; De S; van Hensbergen P; Moravcsik E; Melo JV
    Leukemia; 2007 Mar; 21(3):421-6. PubMed ID: 17252018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythropoietin promotes resistance against the Abl tyrosine kinase inhibitor imatinib (STI571) in K562 human leukemia cells.
    Kirschner KM; Baltensperger K
    Mol Cancer Res; 2003 Nov; 1(13):970-80. PubMed ID: 14638869
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors.
    von Bubnoff N; Veach DR; Miller WT; Li W; Sänger J; Peschel C; Bornmann WG; Clarkson B; Duyster J
    Cancer Res; 2003 Oct; 63(19):6395-404. PubMed ID: 14559829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of transformation by the BCR/ABL oncogene.
    Sattler M; Griffin JD
    Int J Hematol; 2001 Apr; 73(3):278-91. PubMed ID: 11345193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced focal adhesion kinase and paxillin phosphorylation in BCR-ABL-transfected cells.
    Cheng K; Kurzrock R; Qiu X; Estrov Z; Ku S; Dulski KM; Wang JY; Talpaz M
    Cancer; 2002 Jul; 95(2):440-50. PubMed ID: 12124845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct biological impact of dephosphorylation vs. downregulation of p210Bcr-Abl: implications for imatinib mesylate response and resistance.
    Kurzrock R; Talpaz M; Li L; Estrov Z
    Leuk Lymphoma; 2006 Aug; 47(8):1651-64. PubMed ID: 16966279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.